Sofinnova closes €725M fund to back Europe’s late-stage biotechs
Why it matters: Europe has developed a strong early-stage biotech investment ecosystem, but financing becomes more difficult as companies enter expensive clinical trials and approach commercialization. Sofinnova wants to help bridge that gap with larger …